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Community respiratory viruses (CRVs), including respi-
ratory syncytial virus (RSV), inﬂuenza viruses, parainﬂuenza
viruses, adenoviruses, and even rhinoviruses, are signiﬁcant
causes of respiratory infections and accompanying morbidity
and mortality among bone marrow transplant (BMT) recipi-
ents. Although much progress has been made in prevention
of these infections through infection-control programs,
CRV infections that progress to pneumonia contribute
signiﬁcantly to mortality in the posttransplantation period. 
At a symposium in Keystone, Colorado, held in Febru-
ary 2001, speakers from 5 transplantation centers and the
Centers for Disease Control and Prevention reviewed stud-
ies and guidelines on the management of CRV infections in
BMT recipients. Janet A. Englund, MD, reviewed the epi-
demiology of CRV infections and the importance of early
diagnosis, which has been facilitated by the availability of
rapid diagnostic tests. Per Ljungman, MD, PhD, reviewed
data from the prospective CRV epidemiology study, con-
ducted under the auspices of the European Group for Blood
and Marrow Transplantation at its 37 member centers.
W. Garrett Nichols, MD, reviewed the experience with
CRV infections in BMT recipients at the Fred Hutchinson
Cancer Research Center during the past decade and
described 2 ongoing prospective randomized controlled tri-
als of treatment of RSV infection in adult BMT recipients.
Roberta H. Adams, MD, reported on the results of a pilot
trial of preemptive aerosolized ribavirin treatment of RSV
infection in pediatric BMT patients, conducted at the Uni-
versity of Utah, and described the design of an ongoing con-
trolled trial employing the same approach. Clare A.
Dykewicz, MD, MPH, reviewed CRV prevention recom-
mendations from the recently issued guidelines on prevent-
ing opportunistic infections in hematopoietic stem cell
recipients, jointly developed by the Centers for Disease
Control and Prevention, the Infectious Diseases Society of
America, and the American Society for Blood and Marrow
Transplantation. Finally, I reviewed the M.D. Anderson
Cancer Center experience with CRV infections in BMT
recipients and noted our progress in prevention and treat-
ment of these life-threatening infections.
Today, we have a good grasp of the measures we need to
have in place to prevent CRV infections in this vulnerable
patient population. Unfortunately, we currently lack data
from controlled clinical trials that clearly support the efﬁ-
cacy of any particular therapy for serious respiratory tract
infections due to RSV or parainﬂuenza virus in BMT recipi-
ents. There is, however, some indication—primarily for
RSV infection—that early diagnosis and treatment with
aerosolized ribavirin, with or without intravenous RSV
immunoglobulin or monoclonal anti-RSV antibody, may
modify the progression of upper respiratory infections to
pneumonia and reduce mortality. The outcomes of ongoing
trials described here should provide more guidance about
when and how to treat CRV infections in BMT recipients. 
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